DrugPatentWatch Database Preview
ESKATA Drug Profile
» See Plans and Pricing
Which patents cover Eskata, and what generic alternatives are available?
Eskata is a drug marketed by Aclaris and is included in one NDA. There are six patents protecting this drug.
This drug has thirty patent family members in seventeen countries.
The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.
US ANDA Litigation and Generic Entry Outlook for Eskata
Indicators of Generic Entry
Summary for ESKATA
| International Patents: | 30 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 133 |
| Patent Applications: | 3,513 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in ESKATA? | ESKATA excipients list |
| DailyMed Link: | ESKATA at DailyMed |
US Patents and Regulatory Information for ESKATA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ESKATA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 11201608775X | Start Trial |
| Austria | 397452 | Start Trial |
| Australia | 2007203283 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ESKATA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2523731 | 2090024-7 | Sweden | Start Trial | PRODUCT NAME: OSILODROSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING OSILODROSTAT DIHYDROGEN PHOSPHATE; REG. NO/DATE: EU/1/19/1407 20200113 |
| 2523731 | LUC00159 | Luxembourg | Start Trial | PRODUCT NAME: OSILODROSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE DIHYDROGENOPHOSPHATE D'OSILODROSTAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113 |
| 3106463 | 2020C/507 | Belgium | Start Trial | PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
